Lydia Alborn’s Post

Treatment decisions for bladder cancer depend on factors such as the stage and grade of the cancer, the overall health status of the patient, and individual preferences. It's essential for patients to discuss treatment options with their healthcare team to develop a personalized treatment plan tailored to their needs and goals. . . Schedule an appointment today: https://lnkd.in/dEtiBpkA Visit us: drmanojsharmaoncology.com . . . #drmanojkumarsharma #drmanoj #oncologist #oncology #bladdercancer #surgery #chemotherapy #radiationtherapy #immunotherapy #targetedtherapy #cancercheckup #cancerscreening #cancercure #cancertreatment #cancersurvivor #cancercare #cancer #cancertreatment #earlycancerdetection #cancerdetection

A retrospective cohort study published in Annals of Surgical Oncology has analyzed the prognostic significance of surgical margins following pancreaticoduodenectomy for distal cholangiocarcinoma. Out of 133 patients, 21.8% had R1c micro-residual tumors. The study reveals that R1 status does not significantly alter overall survival or recurrence-free survival, contrasting with common presumptions about local recurrence risks. Instead, R1 status correlated more with distant metastasis, suggesting a need for an integrative treatment approach. The findings underline the importance of multidisciplinary care and precision in preoperative planning. For an in-depth understanding, the study is available at https://lnkd.in/et4MWGei #MedicalResearch #CancerTreatment #HealthcareStrategy

Let’s have a quick look at clinical trials into novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   1. Valrubicin This is an intravesical chemotherapy agent, and until recently was the only FDA-approved agent for post-BCG treatment. It was approved in 1998 but not commonly used in real-world practice as it was not widely available and its efficacy was suboptimal.   “Of 90 patients, 19 (21%) had a complete response, including 7 who remained disease-free at the last evaluation, with a median follow-up of 30 months.” (Steinberg et al, The Journal of Urology, 2000).   Tomorrow: pembrolizumab   #medicalinnovation #bladdercancer #HIVEC #CombatMedical    

🚨Highlights from ESMO 2024! Prof Dr Bart Neyns, medical oncologist at UZ Brussel, shares key findings from the proffered paper session on melanoma and skin tumours: - Neoadjuvant therapy demonstrates improved outcomes for melanoma patients with lymph node metastases. - NADINA Trial: Patients with a high pathological response do not require further adjuvant treatment. - Pathological response is identified as a surrogate marker for tailoring post-surgical treatment. Discover these updates.👇 For all ESMO 2024 videos, find the link in the comments! #MediMix #ESMO2024 #SkinCancer #Melanoma #Oncology #CancerResearch #ClinicalTrials

Let’s have a quick look at clinical trials into novel therapy alternatives to radical cystectomy for BCG-unresponsive non-muscle-invasive bladder cancer.   1. Valrubicin This is an intravesical chemotherapy agent, and until recently was the only FDA-approved agent for post-BCG treatment. It was approved in 1998 but not commonly used in real-world practice as it was not widely available and its efficacy was suboptimal.   “Of 90 patients, 19 (21%) had a complete response, including 7 who remained disease-free at the last evaluation, with a median follow-up of 30 months.” (Steinberg et al, The Journal of Urology, 2000).   Tomorrow: pembrolizumab   #medicalinnovation #bladdercancer #HIVEC #CombatMedical    

Exciting news in the fight against brain cancer! A recent Phase II clinical trial using the radiopharmaceutical 177Lu-Dotatate has shown significant progress in extending progression-free survival rates for patients with refractory meningiomas. Key findings include: Nearly 80% of patients remained progression-free after six months. This far exceeds the 26% benchmark from prior studies. 88.9% of patients had overall survival one-year post-treatment. With four infusions every eight weeks, this theranostic approach could represent a new, more effective option for treating aggressively growing meningiomas, where standard treatments like surgery and radiation have limitations. This therapy offers hope for those facing limited options, demonstrating both effectiveness and safety. Read more about the potential impact of radiopharmaceuticals in cancer treatment @ https://lnkd.in/d_ivHrRX 🔬 #PharmaceuticalResearch #Radiopharmaceuticals #CancerTreatment #Meningioma #ClinicalTrials #InnovativeMedicine #PharmaIndustry

‘Studies reveal that #GLP-1 #medications could cut the risk of obesity-related cancers by a fifth.’ (The Times, 2024) Previous research recognised that #obesity #treatment with #bariatric #surgery also reduced the risk of obesity-related cancers (see ref), however, GLP-1 medications show a greater reduction in risk, even with less overall #weight loss.   Presented at the American Society of Clinical Oncology (ASCO) conference in Chicago, these new findings show promise for incorporating GLP-1 drugs into #cancer treatment protocols. 'GLP drugs are very promising and we certainly hope someday they will be a tool in cancer treatment. But before we can say that, we need rigorous clinical trials to test them,' said oncologist Dr. Sherry Shen. Click here to read the full study 👇 https://lnkd.in/eB59j4vR ref: Aminian A, Wilson R, Al-Kurd A, et al. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA. 2022;327(24):2423–2433

We invite you to #publish an article on "Current Trends in Gynecologic Oncology," sharing your valuable insights and expertise. #cheating #Gynecologic #oncology #Ovarian #CancerCare #Endometrial #Cervical #Uterine #Vulvar #Vaginal #Pelvic #Chemotherapy #Radiation #Clinicaltrails

Seeking Professional Opinions: Radical vs. Conservative Dental Approaches for Oncology Patients Pre-IV Bisphosphonate Therapy Dear colleagues, I would appreciate your insights on a critical decision-making aspect in dental care for oncology patients, particularly those diagnosed with multiple myeloma or breast cancer, who are about to commence IV bisphosphonate therapy. The dilemma often arises between performing radical (invasive) procedure such extractions of clinically and radiologically asymptomatic teeth with uncertain long-term prognosis to prevent complications such as medication-related osteonecrosis of the jaw (MRONJ) versus taking a conservative approach and attempting to manage these teeth to preserve function. On one hand, extractions reduce the risk of complications during bisphosphonate therapy in the future. On the other, a conservative approach helps maintain dental function and quality of life for the patient. How do you navigate this decision in your practice? Do you lean toward a more radical or conservative approach, and what factors influence your recommendation? Obviously, there are multiple factors that must be carefully considered, as well as patient should be well informed about potential risk of MRONJ. Looking forward to hearing your experiences and insights! #Oncology #SpecialCareDentistry #Bisphosphonates #DentalCare

Ewing sarcoma is a pediatric bone and soft tissue tumor. A recent study reveals how chemotherapy resistance may be countered by targeting TAM kinase activation with inhibitors like filgotinib and MRX-2843. Promising advancements in treatment efficacy are on the horizon in treating ewing sarcoma! Discover more about these groundbreaking findings in the full article: https://lnkd.in/g9T3qPuD #EwingSarcoma #PediatricOncology #CancerResearch #Chemotherapy #MedicalScience